The effect of omega-3 fatty acids on clinical and paraclinical features of intractable epileptic patients: a triple blind randomized clinical trial

Clinical and Translational Medicine

Table 3 ANCOVA results for comparison of two groups with adjustment of age, gender and baseline measurements

Parameters	Study groups	Mean ± standard error of mean	Median of percent change (%)	Mean difference	P value	95% confidence interval for differences	Effect size
Seizure frequency	Supplement	4.72 ± 1.6	− 80	− 6.91	0.014	[− 11.26, − 2.79]	0.442
Seizure frequency	Placebo	11.64 ± 1.63	0	− 6.91	0.014	[− 11.26, − 2.79]	0.442
TNF-α	Supplement	13.43 ± 4.4	− 38.27	− 43.4	0.002	[− 61.67, − 25.6]	0.703
TNF-α	Placebo	74.14 ± 13.3	77.33	− 43.4	0.002	[− 61.67, − 25.6]	0.703
IL-6	Supplement	2.28 ± 0.37	− 41.23	− 5.21	0.004	[− 7.5, − 3.2]	0.725
IL-6	Placebo	7.53 ± 1.02	46.41	− 5.21	0.004	[− 7.5, − 3.2]	0.725
Epilepsy duration in study period (min)	Supplement	6.64 ± 1.39	− 50	− 6.061	0.009	[− 10.12, − 1.9]	0.408
Epilepsy duration in study period (min)	Placebo	14.36 ± 2.18	0	− 6.061	0.009	[− 10.12, − 1.9]	0.408

All results are based on Bootstrapping Method; Effect size conventions; f = 0.1: small, f = 0.25: medium, f = 0.4: large